| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More | Sarah de Crescenzo | 10/25/19 | National |
| SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study | Sarah de Crescenzo | 10/21/19 | Seattle |
| ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More | Ben Fidler | 10/01/19 | National |
| Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts | Frank Vinluan | 07/18/19 | National |
| Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More | Ben Fidler | 03/29/19 | National |
| VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic | Frank Vinluan | 10/01/18 | San Diego |
| Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies | Frank Vinluan | 03/29/18 | Boston |
| Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks | Ben Fidler | 03/23/18 | National |
| Unum, Homology Plan IPOs, as Unum Reveals Two Patient Deaths | Frank Vinluan | 03/05/18 | Boston |
| Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More | Frank Vinluan | 02/02/18 | National |
| Bio Buyout Spree Continues as SeaGen Bets $614M on Cascadian Cancer Drug | Ben Fidler | 01/31/18 | Seattle |
| ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More | Alex Lash | 12/11/17 | National |
| Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi | Ben Fidler | 11/10/17 | National |
| Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More | Alex Lash | 06/30/17 | National |
| Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More | Alex Lash | 06/23/17 | National |
| SeaGen Ends One Leukemia Drug Trial, Stops Enrolling Three Others | Frank Vinluan | 06/19/17 | Seattle |
| Mersana Plans IPO to Finance Clinical Trials for Breast Cancer Drug | Frank Vinluan | 06/02/17 | Boston |
| VenBio Settles Immunomedics Litigation, SeaGen Nixes Cancer Drug Deal | Frank Vinluan | 05/05/17 | New York |
| AACR Review: Biden Fired Up, Incyte Doubles Up, BMS Up And Down | Alex Lash | 04/06/17 | National |
| Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More | Ben Fidler | 03/10/17 | National |
| Seattle Genetics to Resume Leukemia Drug Trials After FDA Lifts Hold | Frank Vinluan | 03/06/17 | Seattle |
| VenBio-Backed Directors Wrest Control of Immunomedics Board | Frank Vinluan | 03/03/17 | New York |
| Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More | Ben Fidler | 02/17/17 | National |
| Seattle Genetics Puts Up $250M for Immunomedics Cancer Drug Rights | Frank Vinluan | 02/10/17 | Seattle |
| Liver Damage, Patient Deaths Lead FDA to Halt SeaGen Leukemia Trials | Frank Vinluan | 12/27/16 | Seattle |
| Cepheid, Propelled By Seattle Chemists, Sells to Danaher for $4B | David Holley | 09/06/16 | San Francisco |
| Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More | Ben Fidler | 08/05/16 | National |
| Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More | Ben Fidler | 05/27/16 | National |
| Big Bucks, Tiny Bubbles: Ex-Biogen Exec’s Exosome Startup Nabs $80M | Ben Fidler | 11/17/15 | Boston |
